Naplex 2026

NAPLEX 2026 EXAM QUESTIONS WITH CORRECT VERIFIED ANSWERS | 100% PASS (A+ CERTIFIED) Concentration dependent antibiotics (Cmax:MIC) Answer aminoglycosides, quinolones, daptomycin *goal: high peak, low trough dosing strategy: large dose, long interval Exposure-dependent antibiotics (AUC:MIC) Answer vancomycin, macrocodes, tetracyclines, polymyxins *goal: exposure over time dosing strategy: variable Time-dependent antibiotics (Time MIC) Answer B-lactams Goal: maintain drug level MIC for most of the dosing interval Dosing strategies: shorter dosing interval, extended for continuous infusions Penicillin VK Answer PO: first line for strep throat and mild non purulent skin infections Amoxicillin Answer First line for acute otitis media Drug of choice for infective endocarditis prophylaxis before dental procedure used in H. pylori treatment Augmentin (amox/clav) Answer first line for acute otitis media (recurrence) and bacterial sinusitis Dicloxacillin, nafcillin, oxacillin Answer covers MSSA only no renal dose adjustment needed Penicillin G Benzathine Answer Bicillin L-A BBW: not for IV use -- can cause cardiorespiratory arrest and death Indication: Syphillis Piperacillin/tazobactam Answer Zosyn active agains pseudomonas aeruginosa extended infusions (4 hours) can be used to maximize T MIC Cephalosporins Answer *not active against Enterococcus spp. or atypicals - gram negative coverage increases with each generation 1st gen: strep, staph (MSSA), some activity against GNR (PEK) 2nd gen: HNPEK (cefotetean and cefoxitin have added gram-negative anaerobic coverage - B. fragilis) 3rd gen: - cetriaxone, cefotaxime, cefdinir: resistant strep, MSSA, gram-positive anaerobes and resistant HNPEK - ceftazidime: no gram positive activity, covers Pseudomonas 4th gen: cefepime - broad GN activity (HNPEK, CAPES, Pseudomonas) and gram-positive similar to CTX 5th gen: ceftaroline - GN activity similar to CTX and broad GP activity, including MRSA ceftazidime/avibactam ceftolozane/tazobactam Answer similar spectrum to ceftazidime, but added activity against MDR Pseudomonas and MDR GNR *used for MDR GN organisms (including pseudomonas Cefiderocol Answer Siderophore cephalosporin approved for complicated UTI/Pyelo active against E. coli, enterobacter, klebsiella, proteus, pseudomonas Cephalexin (PO) Answer Keflex common uses: skin infections (MSSA), strep throat 1st gen: strep, staph (MSSA), some activity against GNR (PEK) Cefuroxime (PO) Answer common uses: AOM, CAP 2nd gen: HNPEK Cefdinir (PO) Answer common uses: AOM 3rd gen: resistant strep, MSSA, gram-positive anaerobes and resistant HNPEK Cefazolin (IV) Answer common use: surgical prophylaxis 1st gen: strep, staph (MSSA), some activity against GNR (PEK) Cefotetan (Cefotan), Cefoxitin Answer anaerobe coverage (B. fragilis) Common use: surgical prophylaxis (GI procedures) Cefotetan can cause disulfiram like reaction w/ alcohol ingestion 2nd gen: HNPEK (cefotetean and cefoxitin have added gram-negative anaerobic coverage - B. fragilis) Ceftriaxone, Cefotaxime Answer Common use: CAP, meningitis, SBP, pyelonephritis CTX: no renal dose adj, do not use in neonates (0-28 days) 3rd gen: - cetriaxone, cefotaxime, cefdinir: resistant strep, MSSA, gram-positive anaerobes and resistant HNPEK Ceftazidime Answer Fortaz Active against pseudomonas 3rd gen, ceftazidime: no gram positive activity, covers Pseudomonas Cefepime Answer 4th gen: broad GN activity (HNPEK, CAPES, Pseudomonas) and gram-positive similar to CTX Ceftaroline Answer ONLY beta lactam that covers MRSA common uses: CAP, SSTIs Carbapenems Answer Class effects: active against ESBL-producing organisms, seizure risk *all IV only, Ertapenem must be diluted in NS Do not cover: atypical, VRE, MRSA, C. diff, stenotrophomonas ***Ertapenem does NOT cover PEA (pseudomonas, enterococcus, acinetobacter)